|
Status |
Public on Nov 10, 2021 |
Title |
PBMCs, COVID-19 patient, sand-100-1P |
Sample type |
RNA |
|
|
Source name |
PBMC
|
Organism |
Homo sapiens |
Characteristics |
disease state: COVID-19 patient cell type: PBMC
|
Treatment protocol |
treatment protocol was not conducted
|
Growth protocol |
growth protocol was not conducted
|
Extracted molecule |
total RNA |
Extraction protocol |
Total RNA was extracted from PBMCs isolated from peripheral blood, using Qiazol (Qiagen, Hilden, Germany), purified from DNA contamination through a DNase I (Qiagen) digestion step, and further enriched by Qiagen RNeasy columns profiling (Qiagen). The quantity and purity of the RNA was assessed with the NanoDrop spectrophotometer. The quality of the RNA was controlled with the Bioanalyzer.
|
Label |
biotin
|
Label protocol |
According to the manufacturer's protocol
|
|
|
Hybridization protocol |
30-100ng RNA were hybridized following CodeSet hybridization Setup Protocol (MAN-10056-03) On the Prep Station was selected the High Sensitivity protocol .
|
Scan protocol |
Samples were analyzed with the nCounter Digital Analyzer. The data Resolution selected was Max ( max resolution takes 555 images per sample).
|
Description |
Isolation of Human peripheral blood mononuclear cells (PBMCs) obtained from COVID-19 patient
|
Data processing |
RCC files were analyzed using nSolver analysis software (Version 4.0) as the manufacturer’s protocols. Negative and positive controls included in probe sets were used for background thresholding and a geometric mean of internal reference genes used for normalization. Normalized counts were further analyzed by MATLAB R2019b.
|
|
|
Submission date |
Jan 11, 2021 |
Last update date |
Nov 10, 2021 |
Contact name |
andrea sacconi |
Organization name |
regina elena cancer institute
|
Street address |
via elio chianesi
|
City |
rome |
ZIP/Postal code |
00144 |
Country |
Italy |
|
|
Platform ID |
GPL27956 |
Series (1) |
GSE164571 |
Multi-omic approach identifies a transcriptional network coupling innate immune response to proliferation in the blood of COVID-19 cancer patients |
|